Navigation Links
Human Genome Sciences Advances Oncology Portfolio
Date:4/16/2008

ombination with Velcade

(bortezomib) in advanced multiple myeloma, and expects to have data

available in the third quarter of 2008.

-- In December 2007, HGS initiated dosing of approximately 105 patients in

a randomized Phase 2 trial of HGS-ETR1 in combination with paclitaxel

and carboplatin as first-line therapy in advanced non-small cell lung

cancer, and expects to have data available in 2009.

-- Today, HGS announced that it plans by mid-2008 to initiate a randomized

Phase 2 trial of HGS-ETR1 in combination with Nexavar (sorafenib) in

hepatocellular cancer. The study in hepatocellular cancer will begin

with a safety lead-in to assure the safety of this combination therapy

in patients with hepatocellular cancer who are infected with hepatitis

C.

About the HGS IAP Inhibitor Program

In December 2007, the HGS oncology portfolio was further strengthened by a licensing and collaboration agreement between HGS and Aegera Therapeutics Inc. This agreement provides HGS with exclusive worldwide rights (excluding Japan) to develop and commercialize HGS1029 (formerly AEG40826) and other small- molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology. Preclinical studies of HGS1029 in combination with the Company's TRAIL receptor antibodies demonstrated dramatic synergistic activity against a number of cancer types. HGS1029 has also shown significant anti-tumor activity alone and in combination with other agents in a broad range of cancers. HGS expects to initiate a Phase 1 clinical trial of HGS1029 by mid-2008 and plans to develop its TRAIL receptor antibodies and IAP inhibitors in combination with one another and in combination with other therapeutic agents.

About HGS-ETR1 and HGS-ETR2

HGS-ETR1 and HGS-ETR2 are agonistic human monoclonal antibodies that directly induce cancer-cell death by specifically binding to and activating th
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the six months ended June 30, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... , Announced top-line results related to the eight ... enrolled in the Phase 2 iDEAL Study evaluating ...
(Date:8/29/2014)... 2014 A major challenge before new ... dense realm of Boston-Cambridge, is gaining visibility that can ... Sherley, the Director of Boston’s Adult Stem Cell Technology ... national visibility of his company an important priority since ... addition to a social media marketing campaign ...
(Date:8/28/2014)... Ca. (PRWEB) August 28, 2014 Best ... rating for an alcohol-based hand sanitizer, asks food processors ... by comparing the hand sanitizer they’re currently using to ... . Hand hygiene is critical to fighting cross-contamination and ... Best Sanitizers believes there are key criteria that ...
(Date:8/28/2014)... , Aug. 28, 2014 ... a new market research report ... Whole Exome Sequencing ... (Library Preparation, Target Enrichment), by ... by Synthesis), by Application (Cancer, ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13
... Crossing System after recent CE clearance Ovalum Ltd., ... announced today the launch of sales of its ... the peripheral vasculature. The devices are intended ... arterial blockage (CTO). These obstructions are hard to ...
... NORWALK, Conn., July 9 According to a new ... and acquisitions were,announced in the health care industry during ... 223 deals announced in the prior quarter. Based on,preliminary ... fund the,second quarter,s M&A activity, a 209% increase over ...
... Abt Bio-Pharma Solutions, Inc.,(ABS), a global ... commercialization solutions, is pleased to announce that ... strategy, has been promoted to,Executive Director and ... Windham-Bannister, who has been appointed,President & CEO ...
Cached Biology Technology:Ovalum Ltd. Announces Sales Launch of CiTop™ Product-Line in Europe 2Second Quarter Health Care M&A Strongest In Years According To New Report From Irving Levin Associates, Inc. 2Second Quarter Health Care M&A Strongest In Years According To New Report From Irving Levin Associates, Inc. 3Second Quarter Health Care M&A Strongest In Years According To New Report From Irving Levin Associates, Inc. 4Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister 2Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister 3
(Date:8/29/2014)... a cell,s nucleus, chromosomal DNA is tightly bound ... biologists call chromatin. Until about two decades ago, ... mere packing material around which the glamorous DNA ... a greater appreciation for how DNA/histone interactions govern ... research institutions studying the sequence of the genome ...
(Date:8/28/2014)... of bacterial culprits that may drive inflammatory bowel diseases ... patients, own intestinal immune responses as a guide. , ... Cell . , Trillions of bacteria exist within ... in the development and progression of IBD. Yet it,s ... affect a person,s susceptibility to IBD and its potential ...
(Date:8/28/2014)... Clinic researcher and his collaborators have developed an online ... process of re-engineering cells for biomedical investigation. CellNet is ... to aid stem cell engineering. Details of CellNet and ... two back-to-back papers in the journal Cell . ... uses for all types of cell-based investigations and can ...
Breaking Biology News(10 mins):'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Yale study identifies possible bacterial drivers of IBD 2New tool aids stem cell engineering for medical research 2
... renewable fuel source could generate enough electricity to meet ... consumption needs and lead to a significant reduction in ... today, Thursday, 24 July, in the Institute of Physics, ... ,Cow Power: The Energy and Emissions Benefits of Converting ...
... study shows that popular fish oil supplements have an ... in human skin. But whether that effect is detrimental, ... omega-3 fatty acids found in fish oils are widely ... to chronic inflammation because of their anti-inflammatory properties. But ...
... heart grow fonder, but endurance exercise seems to make it ... of Medicine in St. Louis, older people who did endurance ... much younger hearts. The researchers also showed that by one ... , "We know that the heart deteriorates as people ...
Cached Biology News:Cow power could generate electricity for millions 2Scientists suspect omega-3 fatty acids could slow acute wound healing 2Scientists suspect omega-3 fatty acids could slow acute wound healing 3Scientists suspect omega-3 fatty acids could slow acute wound healing 4Exercise could be the heart's fountain of youth 2Exercise could be the heart's fountain of youth 3